The dilutive offering at a discount to market price creates near-term selling pressure, but the extended cash runway into 2029 removes financing overhang for a pre-revenue biotech. Monitor for the underwriters' greenshoe exercise and any insider participation. The Phase 1 SL-325 data provides a positive catalyst backdrop, but the primary endpoint readout from the Phase 2b RECEPTIVE-CD1 trial is not expected until H1 2028 — a long wait with no near-term catalysts.
Price Chart
Executive Summary
Shattuck Labs is conducting a $75M underwritten public offering of 10.9M common shares and 7.9M pre-funded warrants at $4.00/share, a ~6.3% discount to the $4.27 prior close. The company simultaneously disclosed that ~96% of warrants from its August 2025 PIPE have been exercised, generating ~$54.9M in gross proceeds, extending cash runway into 2029. The offering adds ~$70.5M net proceeds, but immediate dilution to new investors is $2.08/share (52% of offering price).
Key Facts
- Offering of 10,879,376 common shares and 7,870,624 pre-funded warrants at $4.00 per share, raising $75M gross / $70.5M net
- Offering price represents a ~6.3% discount to the $4.27 prior close on June 9, 2026
- Immediate dilution of $2.08 per share (52% of offering price) for new investors
- Pro forma net tangible book value per share after offering: $1.92 (vs. $1.27 pre-offering)
- Underwriters have 30-day option for an additional 2,812,500 shares
- Concurrent warrant exercises: ~50.6M common stock warrants exercised (96% of Aug 2025 PIPE), generating ~$54.9M gross proceeds
- Cash runway extended into 2029, per company guidance (including warrant exercise proceeds)
- Pre-funded warrants have nominal $0.0001 exercise price, no public trading market expected
- Positive Phase 1 SL-325 data announced June 8, 2026 — no serious AEs, complete DR3 occupancy at all doses, quarterly dosing potential
Financial Impact
$75M gross / $70.5M net proceeds from offering; $54.9M from warrant exercises; combined cash ~$215M pro forma (est.)
Risk Factors
- Immediate 52% dilution per share for new investors
- No public market for pre-funded warrants limits liquidity for those holders
- Massive warrant overhang: 47.5M common warrants and 38.4M pre-funded warrants outstanding as of March 31, 2026
- Pre-revenue biotech with no approved products; Phase 2b data not expected until H1 2028
- Stock price volatility typical for clinical-stage biotech; potential for further dilutive offerings
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-266618 |
| Document: 0001193125-26-266618-index-headers.html | 0001193125-26-266618 |
| Document: 0001193125-26-266618-index.html | 0001193125-26-266618 |
| Document: 0001193125-26-266618.txt | 0001193125-26-266618 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 11w ago | 8-K | $7.18 $7.45 | ▲ +3.76% | ▲ +4.16% | $5.54 (−22.84%) |
Aug 11, 2026 11w ago | Press Release | $7.18 $7.45 | ▲ +3.76% | ▲ +4.16% | $5.54 (−22.84%) |
Jul 7, 2026 15w ago | Insider Cluster | $6.88 $6.29 | ▼ −8.58% | ▼ −9.44% | $5.54 (−19.48%) |
Jul 2, 2026 16w ago | Insider Cluster | $7.05 $7.03 | ▼ −0.28% | ▼ −1.21% | $5.54 (−21.42%) |
Jun 11, 2026 19w ago | 8-K | $4.18 $4.74 | ▼ −13.40% | ▼ −12.96% | $5.54 (−32.54%) |
Jun 11, 2026 19w ago | Institutional Cluster | $4.18 $4.74 | ▼ −13.40% | ▼ −12.96% | $5.54 (−32.54%) |
Jun 11, 2026 19w ago | 424B5 | $4.18 $4.74 | ▼ −13.40% | ▼ −12.96% | $5.54 (−32.54%) |
Jun 10, 2026 19w ago | Press Release | $4.13 $4.33 | ▼ −4.84% | ▼ −1.41% | $5.54 (−34.14%) |
Jun 9, 2026 19w ago | 424B5 | $4.13 $4.33 | ▼ −4.84% | ▼ −1.41% | $5.54 (−34.14%) |
Jun 9, 2026 19w ago | 8-K | $4.13 $4.33 | ▲ +4.84% | ▲ +1.41% | $5.54 (+34.14%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers